PMID- 27281066
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20220419
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 95
IP  - 23
DP  - 2016 Jun
TI  - Efficacy of Anti-TNFalpha in Severe and Refractory Neuro-Behcet Disease: An 
      Observational Study.
PG  - e3550
LID - 10.1097/MD.0000000000003550 [doi]
LID - e3550
AB  - To report the safety and efficacy of anti-tumor necrosis factor alpha (TNFalpha) therapy 
      in severe and refractory neuro-Behcet disease (NBD) patients.Observational, 
      multicenter study including 17 BD patients (70.6% of male, with a median age of 
      39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous 
      immunosuppressant and treated with anti-TNFalpha (infliximab 5 mg/kg [n = 13] or 
      adalimumab [n = 4]). Complete remission was defined by the disappearance of all 
      neurological symptoms and by the improvement of radiological abnormalities at 12 
      months.Overall improvement following anti-TNF was evidenced in 16/17 (94.1%) 
      patients including 6 (35.3%) complete response and 10 (58.8%) partial response. 
      The median time to achieve remission was 3 months (1-6). The median Rankin score 
      was 2 (1-4) at the initiation of anti-TNFalpha versus 1 (0-4) at the time of 
      remission (P = 0.01). Corticosteroids have been stopped in 4 (23.5%) patients, 
      and reduced by more than 50% as compared with the dosage at baseline in 10 
      (58.8%) patients. Side effects occurred in 23.5% of patients and required 
      treatment discontinuation in 17% of cases.TNF blockade represents an effective 
      therapeutic approach for patients with severe and refractory NBD, a difficult to 
      treat population.
FAU - Desbois, Anne Claire
AU  - Desbois AC
AD  - From APHP Groupe Hospitalier Pitie-Salpetriere Paris, France: Service de Medecine 
      Interne et Immunologie Clinique (ACD, PC, DS), Service de Neurologie (RD), and 
      Service de Medecine Interne 2 (FC) Service de Neuroradiologie Diagnostique et 
      Fonctionnelle (AB); DHU Inflammation Immunopathologie, Biotherapie, Universite 
      Pierre et Marie Curie, Paris, France (ACD, PC, DS); Inserm U1127, CNRS UMR 7225, 
      Sorbonne Universites, Universite Pierre et Marie Curie Paris 6 and UMR S 1127, 
      Institut du Cerveau et de la Moelle epiniere, ICM, Inria Paris-Rocquencourt, 
      F-75013, Paris, France (AB); Service de Medecine Interne, CHU Grenoble, France 
      (AD); Service de Medecine Interne, Groupement Hospitalier-Hopital Edouard 
      Herriot, Lyon, France (LP); Service de Medecine Interne, Hopital Claude Huriez, 
      CHRU Lille, France (EH, ML, DL) ; Service de Medecine Interne Hopital Foch, 
      Suresnes, France (BS, FA); Service de Rhumatologie, CHU Le Kremlin Bicetre, 
      France (XM) ;Service de Medecine Interne, CHU Bois-Guillaume, Rouen, France (IM); 
      and Rheumatology Unit, Department of Internal Medicine, Reggio Emilia, Italy (OA, 
      CS).
FAU - Addimanda, Olga
AU  - Addimanda O
FAU - Bertrand, Anne
AU  - Bertrand A
FAU - Deroux, Alban
AU  - Deroux A
FAU - Perard, Laurent
AU  - Perard L
FAU - Depaz, Raphael
AU  - Depaz R
FAU - Hachulla, Eric
AU  - Hachulla E
FAU - Lambert, Marc
AU  - Lambert M
FAU - Launay, David
AU  - Launay D
FAU - Subran, Benjamin
AU  - Subran B
FAU - Ackerman, Felix
AU  - Ackerman F
FAU - Mariette, Xavier
AU  - Mariette X
FAU - Cohen, Fleur
AU  - Cohen F
FAU - Marie, Isabelle
AU  - Marie I
FAU - Salvarini, Carlo
AU  - Salvarini C
FAU - Cacoub, Patrice
AU  - Cacoub P
FAU - Saadoun, David
AU  - Saadoun D
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/*therapeutic use
MH  - Adult
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Behcet Syndrome/diagnosis/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Infliximab/*therapeutic use
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*antagonists & inhibitors
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4907644
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2016/06/10 06:00
MHDA- 2017/02/09 06:00
PMCR- 2016/06/10
CRDT- 2016/06/10 06:00
PHST- 2016/06/10 06:00 [entrez]
PHST- 2016/06/10 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/06/10 00:00 [pmc-release]
AID - 00005792-201606070-00004 [pii]
AID - 10.1097/MD.0000000000003550 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2016 Jun;95(23):e3550. doi: 10.1097/MD.0000000000003550.